Literature DB >> 21793567

Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901.

Payal R Sheth1, Yuqi Liu, Thomas Hesson, Jia Zhao, Lev Vilenchik, Yan-Hui Liu, Todd W Mayhood, Hung V Le.   

Abstract

Kinases catalyze the transfer of γ-phosphate from ATP to substrate protein residues triggering signaling pathways responsible for a plethora of cellular events. Isolation and production of homogeneous preparations of kinases in their fully active forms is important for accurate in vitro measurements of activity, stability, and ligand binding properties of these proteins. Previous studies have shown that MEK1 can be produced in its active phosphorylated form by coexpression with RAF1 in insect cells. In this study, using activated MEK1 produced by in vitro activation by RAF1 (pMEK1(in vitro)), we demonstrate that the simultaneous expression of RAF1 for production of activated MEK1 does not result in stoichiometric phosphorylation of MEK1. The pMEK1(in vitro) showed higher specific activity toward ERK2 protein substrate compared to the pMEK1 that was activated via coexpression with RAF1 (pMEK1(in situ)). The two pMEK1 preparations showed quantitative differences in the phosphorylation of T-loop residue serine 222 by Western blotting and mass spectrometry. Finally, pMEK1(in vitro) showed marked differences in the ligand binding properties compared to pMEK1(in situ). Contrary to previous findings, pMEK1(in vitro) bound allosteric inhibitors U0126 and PD0325901 with a significantly lower affinity than pMEK1(in situ) as well as its unphosphorylated counterpart (npMEK1) as demonstrated by thermal-shift, AS-MS, and calorimetric studies. The differences in inhibitor binding affinity provide direct evidence that unphosphorylated and RAF1-phosphorylated MEK1 form distinct inhibitor sites.
© 2011 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793567     DOI: 10.1021/bi200542r

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

Review 1.  Signaling pathways as therapeutic targets in biliary tract cancer.

Authors:  Jennifer Yang; Matthew R Farren; Daniel Ahn; Tanios Bekaii-Saab; Gregory B Lesinski
Journal:  Expert Opin Ther Targets       Date:  2017-03-17       Impact factor: 6.902

Review 2.  Assessing adaptation of the cancer kinome in response to targeted therapies.

Authors:  Jon S Zawistowski; Lee M Graves; Gary L Johnson
Journal:  Biochem Soc Trans       Date:  2014-08       Impact factor: 5.407

3.  Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.

Authors:  Georgia Hatzivassiliou; Jacob R Haling; Huifen Chen; Kyung Song; Steve Price; Robert Heald; Joanne F M Hewitt; Mark Zak; Ariana Peck; Christine Orr; Mark Merchant; Klaus P Hoeflich; Jocelyn Chan; Shiuh-Ming Luoh; Daniel J Anderson; Mary J C Ludlam; Christian Wiesmann; Mark Ultsch; Lori S Friedman; Shiva Malek; Marcia Belvin
Journal:  Nature       Date:  2013-08-11       Impact factor: 49.962

4.  Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.

Authors:  Peter Orth; Li Xiao; Lorraine D Hernandez; Paul Reichert; Payal R Sheth; Maribel Beaumont; Xiaoyu Yang; Nicholas Murgolo; Grigori Ermakov; Edward DiNunzio; Fred Racine; Jerzy Karczewski; Susan Secore; Richard N Ingram; Todd Mayhood; Corey Strickland; Alex G Therien
Journal:  J Biol Chem       Date:  2014-05-12       Impact factor: 5.157

5.  Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.

Authors:  Gary L Johnson; Timothy J Stuhlmiller; Steven P Angus; Jon S Zawistowski; Lee M Graves
Journal:  Clin Cancer Res       Date:  2014-03-24       Impact factor: 12.531

6.  A Protoberberine derivative HWY336 selectively inhibits MKK4 and MKK7 in mammalian cells: the importance of activation loop on selectivity.

Authors:  Namil Kim; Jeongyeon Park; Changdev G Gadhe; Seung Joo Cho; Youngjin Oh; Donghyun Kim; Kiwon Song
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

Review 7.  MEK and the inhibitors: from bench to bedside.

Authors:  Akintunde Akinleye; Muhammad Furqan; Nikhil Mukhi; Pavan Ravella; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-04-12       Impact factor: 17.388

8.  An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery.

Authors:  Pawel Linke; Kwame Amaning; Melanie Maschberger; Francois Vallee; Valerie Steier; Philipp Baaske; Stefan Duhr; Dennis Breitsprecher; Alexey Rak
Journal:  J Biomol Screen       Date:  2015-12-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.